Target (CBDY) Cash from Financing Activities (2013 - 2026)
Target (CBDY) reported Cash from Financing Activities of $240570.0 for Q1 2026, up 143.16% year-over-year from $98936.4 in Q1 2025, and up 35374.19% quarter-over-quarter from -$682.0 in Q4 2025.
Target (CBDY) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Cash from Financing Activities data on file, last reported at $240570.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $240570.0, up 143.16% year-over-year; the trailing twelve-month figure through Mar 2026 was -$266804.0 (up 51.15% YoY), and the FY2025 annual result was -$1.1 million, down 45.82% from the prior year.
- Cash from Financing Activities climbed to $240570.0 in Q1 2026 per CBDY's latest filing, from -$682.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $554550.0 in Q1 2023 and troughed at -$741500.0 in Q1 2024.
- A 5-year average of -$44993.8 and a median of $983.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 703.93% in 2023, then plunged 9418.82% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $193087.0 in 2022, then plunged by 101.06% to -$2040.0 in 2023, then surged by 342.25% to $4942.0 in 2024, then tumbled by 113.8% to -$682.0 in 2025, then soared by 35374.19% to $240570.0 in 2026.
- Business Quant data shows CBDY's Cash from Financing Activities at $240570.0 in Q1 2026, -$682.0 in Q4 2025, and -$8135.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Target | - | - | 191,787.00 | 240,570.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 240,570.00 |
| Mar 31, 2026 | 240,570.00 |
| Dec 31, 2025 | -682.00 |
| Dec 31, 2025 | -682.00 |
| Sep 30, 2025 | -8,135.00 |
| Sep 30, 2025 | -8,135.00 |
| Jun 30, 2025 | -498,557.00 |
| Jun 30, 2025 | -498,557.00 |
| Mar 31, 2025 | -557,440.00 |
| Mar 31, 2025 | -557,440.00 |
| Dec 31, 2024 | 4,942.00 |
| Dec 31, 2024 | 4,942.00 |
| Sep 30, 2024 | 983.00 |
| Sep 30, 2024 | 983.00 |
| Jun 30, 2024 | 5,350.00 |
| Jun 30, 2024 | 5,350.00 |
| Mar 31, 2024 | -741,500.00 |
| Mar 31, 2024 | -741,500.00 |
| Dec 31, 2023 | -2,040.00 |
| Dec 31, 2023 | -2,040.00 |